GB Sciences Inc (OTCMKTS:GBLX) Submits Its Patent Application For Cannabis-Based Chronic Pain Treatments

GB Sciences Inc (OTCMKTS:GBLX) announced on Wednesday that its subsidiary GBS Global Biopharma, Inc. filed a patent application for its chronic pain formulations made using cannabis extracts.

The newly filed patent covers the proprietary cannabis-based formulations that are designed using functional assay data and molecular docking simulations. A lot of research and development is currently being poured into the pursuit of new pain treatments which might help curb opioids addiction and opioid-related deaths. 

Opioids are currently used to treat chronic pain but their major disadvantage is that they are highly addictive. More than 1.7 Million Americans are affected by opioid addiction and about 50,000 people die annually from opioid-related causes such as overdose. GB Sciences’ new patent for cannabis-based chronic pain treatment presents a chance to reduce and possibly eliminate the need for opioids.

“Unlike others who are narrowly focused on using a very limited number of cannabinoids for the treatment of pain, we embraced the complexity of whole-plant cannabis extracts,” stated Dr. Andrea Small-Howard, the Chief Science Officer at GBS.

GB Sciences’ patent promises to deliver pain relief alternatives without toxicity drawbacks

Dr. Andrea also noted that GBS developed complex combinations of TRP ligands that are based on Cannabis and can desensitize numerous TRP channels at the same time. The complex compounds are also designed to perform effectively while at the same time avoiding the numbness and neural toxicity that results from capsaicin-based pain relievers applied topically.

GBS has been working on the project together with its research partners from Chaminade University. They are the first to model the cannabidiol and myrcene putative TRPV1-binding sites. Cannabidiol and Myrcene are among the active ingredients that GBS includes in the chronic pain-targeting complex mixtures.

The development team also leveraged the information that they secured from the TRPV1-binding pockets to identify the pain-relieving advantages of the compounds. GB Sciences is one of the companies that have been carrying out cannabis-related research to solve some of the common health conditions. The recently filed patent therefore represents significant progress not only for the company but also for the cannabis industry and also the health sector.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

GB Sciences Inc (OTCMKTS:GBLX) To Conduct Cannabis Use And Awareness Seminars GB Sciences, Inc. (OTCQB:GBLX) Initiates A New Next Level Drug Discovery Project With The University Of Athens GB Sciences Inc (OTCMKTS:GBLX) Associates With Cura Cannabis Solutions

Pin It on Pinterest